Introduction:
P. vivax (Pv) is the second major cause of malaria, after P. falciparum (Pf). There is an increasing recognition that Pv can be associated with severe disease and serious complications in pregnancy, and carries a major health, social and economic burden.
Diagnosis and clinical management of Pv malaria can be difficult, and the control and elimination of Pv presents special challenges.
After inoculation by Anopheles mosquitoes, sporozoites migrate to the liver and infect hepatocytes. Over 7-10 days, parasites develop and divide into merozoites that are released into the bloodstream where they invade reticulocytes and replicate inside them, commencing the (48 hour) blood-stage of infection. Clinical illness develops during the blood-stage and the great majority of drugs target this developmental stage. An important feature of Pv, which differs from Pf, is the occurrence of dormant hypnozoites in the liver that can reactivate weeks, months or years later to initiate new episodes of blood-stage infection, presenting a major challenge to treatment, control and elimination.
Epidemiology and clinical features
Pv has a wide geographical distribution with an estimated 2.5 billion individuals at risk 1 . The wider distribution of Pv than Pf may be due to hypnozoites and better survival in Anopheles at lower temperatures and higher altitudes. The greatest burden is in central Asia (82%); Southeast Asia (9%), the Americas (6%), and Africa (3%). Most of those at risk (~1.5 billion) live in areas of unstable transmission where risk of Pv infection is very low. Estimates of total Pv infections range from 71 to 391 million infections/year 2 . It is also unclear how many Pv infections progress to clinical disease as afebrile parasitemia is common, but studies suggest that Pv infection and illness are more common in children and pregnant women than non-pregnant adults 3, 4 . The low prevalence of Pv in Africa is attributed to the high frequencies of Duffy negativity, which renders individuals largely refractory to Pv; 5 Duffy antigen is an important receptor for merozoite invasion of reticulocytes. Southeast Asian ovalocytosis may also protect against Pv infection and clinical disease 6 .
The clinical presentation in children with uncomplicated Pv malaria varies depending on age
and cannot be easily differentiated from other infectious diseases 7 . A high index of suspicion is necessary for diagnosis in low transmission settings. In all age groups, symptomatic infections commonly cause fever, chills and headache; in infants fever may be the only G6PD-deficiency is an X-linked heritable condition; females may manifest a heterozygous genotype in which only a proportion of the erythrocytes are G6PD-deficient making it difficult to accurately assess the level of deficiency 12
Immunity and vaccines
The incidence of symptomatic Pv-malaria and Pv density and prevalence decreases with age, reflecting the acquisition of immunity from repeated exposure Although these will not protect against Pv, lessons learned from these trials will be valuable for advancing Pv vaccines
15
.
Challenges for elimination
There has been a renewed impetus in malaria elimination programs, with eradication as the long-term goal. There has been a major reduction in malaria globally over the last decade, through established interventions of long-lasting insecticide-treated bed nets, improved diagnosis and treatment, insecticides, and intermittent preventive-treatment in some settings.
However, there are significant challenges for control of Pv (summarized in Table 1 ), and elimination cannot be achieved with current approaches. Where Pf and Pv malaria co-exist, the impact of established control interventions has often been greater for Pf. Detection and clearance of hypnozoite carriage is a major challenge, as failure to clear hypnozoites in populations will result in ongoing transmission, and migrant populations may carry infections into disease-free regions. There is no population screening test for hypnozoites and it is not possible to identify asymptomatic carriers of hypnozoites. Better knowledge of epidemiology and strengthened surveillance systems and tools may enable the development of strategies for identifying and targeting high risk groups. Sub-optimal sensitivity of diagnostics is a further significant barrier to population screening and treatment in elimination programs. Tests that are sensitive enough to detect asymptomatic Pv infections, and reliable tests for G6PD-deficiency prior to administering primaquine would facilitate enhanced control and elimination.
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Future
A renewed global effort against Pv, including research and programmatic activities, raises hopes that ongoing progress in control will be achieved in the coming decade. However, there are many urgent needs in order to achieve more effective control and, ultimately, elimination in many regions. New drugs to replace primaquine that do not cause haemolysis, improving primaquine treatment regimens for compliance, tests for G6PD-deficiency, more sensitive and specific RDTs, and greater knowledge of epidemiology and transmission would greatly aid control and elimination efforts. In the longer term, an effective vaccine could be transformative for control and elimination efforts. 
